A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of and Xience Everolimus Eluting Stent to Evaluate Efficacy and Safety in Coronary Artery Disease

Trial Profile

A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of and Xience Everolimus Eluting Stent to Evaluate Efficacy and Safety in Coronary Artery Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms meriT-V
  • Sponsors Meril Life Sciences
  • Most Recent Events

    • 16 Oct 2016 Status changed from recruiting to completed.
    • 29 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top